Clinical Outcomes After Stereotactic Microwave Ablation for Colorectal Liver Metastases: Single-Center Experience

Clicks: 1
ID: 315745
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #329 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Colorectal cancer (CRC) is the third most common cancer worldwide, with 25-30% of patients develop liver metastases (CRLM). Although hepatic resection remains the preferred treatment, recurrence occurs in 50-70% of cases. Thermal ablation is increasingly used for unresectable and deep seeded metastases < 3cm. Stereotactic microwave ablation (SMWA) has emerged as a highly precise ablation technique offering planning, navigation and validation during the intervention and the possibility to treat invisible lesions by MRI fusion. Aims A comprehensive analysis of patients undergoing SMWA for CRLM aims to identify factors influencing recurrence, oncological outcome and overall survival. Methods Retrospective analysis of a cohort of 89 patients treated at the Bern University Hospital for CRLM with SMWA between 2014 and 2024 Results A total of 89 patients underwent SMWA, with a mean age of 65.5 years. A total of 56 (62.9%) patients presented with synchronous CRLM at the time of SMWA. A total of 172 lesions in 105 interventions were treated. Post-interventional complications occurred in 5 (5.6%) patients. The overall survival, from the first treatment to last Follow-up was 35.6 (±22) months, disease progression was seen in 65 (73%) patients, whereas local recurrence after SMWA was observed in 30 (17.4%) patients, with a mean recurrence-free survival of 7.8 (±5.2) months. Fifteen (50%) of patients with local recurrence were treated with subsequent surgical resection. The influence of the ablation margin using an ablation validation software and a potential correlation with tumor size and anatomic location will now be assessed in order to identify risk factors for recurrence. Conclusion In this cohort, post-interventional complications were infrequent, and both overall survival and local recurrence rates were consistent with those reported in the literature following ablation or resection. SMWA for CRLM represents a safe and effective local treatment option.
Reference Key
openalex_W7163339250 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Fiore, S Gloor, G Beldi, D Candinas, A Komarek, L Anja
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag055.028
URL
https://doi.org/10.1093/bjs/znag055.028
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.